[ 1 ] Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression[J]. Int J Oncol, 2005, 27(5): 1329-1339.
[2]
[ 2 ] Schally AV, Varga JL, Engel JB, et al. Antagonists of growth hormone releasing hormone: an emerging new therapy for cancer[J]. Nat Clin Pract Endocrinol Metab, 2008, 4(1): 33-43.
[3]
[ 3 ] Havt A, Schally AV, Halmos G, et al. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues[J]. PNAS, 2005, 102 (48): 17424-17429.
[4]
[ 4 ] Matsubara S, Sato M, Mizobuchi M, et al. Differential gene expression of growth (GH) hormone-releasing hormone (GRH) and GRH receptor in various rat tissues[J]. Endocrinology, 1995, 136(9): 4147-4150.
[5]
[ 5 ] Morel G, Gallego R, Boulanger L, et al. Restricted presence of the growth hormone releasing hormone receptor to somatotropes in rat and human pituitaries[J]. Neuroendocrinology, 1999, 70(2): 128-136.
[6]
[ 6 ] Gallego R, Pintos E, García-Caballero T, et al. Cellular distribution of growth hormone-releasing hormone receptor in human reproductive system and breast and prostate cancers[J]. Histol Histopathoi, 2005, 20(3): 697-706.
[7]
[ 7 ] Ziegler CG, Brown JW, Schally AV, et al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues[J]. PNAS, 2009, 106(37): 15879-15884.
[8]
[ 8 ] Schulz S, R？cken C, Schulz S. Immunocytochemical localisation of plasma membrane GHRH receptors in human tumours using a novel anti-peptide antibody[J]. Eur J Cancer, 2006, 42 (14): 2390-2396.
[9]
[ 9 ] Lacroix A, Ndiaye N, Tremblay J, et al. Ectopical and abnormal hormone receptors in adrenal Cushing’s syndrome[J]. Endocr Rev, 22(1): 75-110.
[10]
Chabre O, Liakos P, Vivier J, et al. Cushing’s syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma: insights into hormonal control of adrenocortical tumorigenesis[J]. Clin Endocrinol Metab, 1998, 83(9): 3134-3143.
[11]
Lacroix A, Bourdeau I, Lampron A, et al. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction[J]. Clin Endocrinol, 2010, 73(1): 1-15.
[12]
Ye P, Mariniello B, Mantero F, et al. G-protein-coupled receptors in aldosterone-producing adenomas： a potential cause of hyperaldosteronism[J]. J Endocrinol, 2007, 195(1): 39-48.
[13]
Mazzuco TL, Chabre O, Feige JJ, et al. Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis[J]. Mol Cell Endocrinol, 2007(265-266): 23-28.
[14]
Mazzuco TL, Chabre O, Feige JJ, et al. Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and cushing’s syndrome features[J]. J Clin Endocrinol Metab, 2006, 91(1): 196-203.
[15]
Lacroix A, N’Diaye N, Mircescu H, et al. The diversity of abnormal hormone receptors in adrenal Cushing’s syndrome allows novel pharmacological therapies[J]. Braz J Med Biol Res, 2000, 33(10): 1201-1209.
[16]
Assie G, Louiset E, Sturm N, et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal cushing’s syndrome[J]. J Clin Endocrinol Metab, 2010, 95(10): E253-E262.
[17]
Cartier D, Lihrmann I, Parmentier F, et al. Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing’s syndrome[J]. J Clin Endocrinol Metab, 2003, 88(1): 248-254.
[18]
Louiset E, Contesse V, Groussin L, et al. Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing’s syndrome[J]. J Clin Endocrinol Metab, 2006, 91(11): 4578-4586.
[19]
Louiset E, Isvi K, Gasc JM, et al. Ectopic expression of serotonin7 receptors in an adrenocortical carcinoma co-secreting renin and cortisol[J]. Endocr Relat Cancer, 2008, 15(4): 1025-1034.
[20]
Giuliani L, Lenzini L, Antonello M, et al. Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism[J]. J Clin Endocrinol Metab, 2009, 94(2): 684-690.
[21]
Barabutis N, Tsellou E, Schally AV, et al. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor[J]. PNAS, 2007, 104 (13): 5575-5579.
[22]
Kiaris H, Chatzistamou I, Schally AV, et al. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor[J]. Proc Natl Acad Sci USA, 2003, 100(16): 9512-9517.
[23]
Freddi S, Arnaldi G, Fazioli F, et al. Expression of growth hormone releasing hormone receptor splicing variants in human primary adrenocortical tumours[J]. Clin Endocrinol, 2005, 62(5): 533-538.
